A bigger fish for palaeontogists to fry…

A chance find in a quarry led to the discovery that Leedsichthys problematicus grew up to 50ft long – double previous estimatesAn international team of scientists has uncovered the remains of the world's largest fish. The 50ft Leedsichthys problematicus swam the oceans of the Jurassic era more than 160m years ago, sweeping up shoals of plankton through giant, mesh-covered gills. Leedsichthys was eventually wiped out by the same catastrophe that killed the dinosaurs 66m years ago.The discovery by the team – led by Professor Jeff Liston of the National Museums of Scotland – is intriguing because it reveals that just as dinosaurs on land were going through major changes which saw the appearance of animals of vast dimensions – creatures that included Diplodocus, Apatosaurus and Brachiosaurus – reptiles in the sea had also started to grow to vast proportions in the Jurassic."The process is known as gigantism," said Liston. "It was known about in land animals at the time but we had no way of knowing if a parallel process occurred in the oceans. We now know that it did – though the reason for appearance of these gigantic beasts, both on land and in the water, is not clear at present."Pieces of Leedsichthys fossils were first found by the British collector Alfred Leeds in 1889. Similar remains were subsequently found at other sites, from northern Germany to Normandy, Mexico and the Atacama desert in Chile. However, knowledge of ...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Evolution Dinosaurs Editorial The Observer Fossils Zoology Science Source Type: news

Related Links:

CONCLUSIONS Upfront GKS resulted in good tumor control as well as a low rate of adverse radiation effects in the whole group. Patients with CD achieved a faster and far better remission rate after upfront GKS in comparison to patients with acromegaly. GKS can be considered as an upfront treatment in carefully selected patients with CD who are unwilling or unable to undergo resection, but it has a more limited role in acromegaly. PMID: 30117768 [PubMed - as supplied by publisher]
Source: Journal of Neurosurgery - Category: Neurosurgery Authors: Tags: J Neurosurg Source Type: research
CONCLUSION: the history we report, therefore, confirms previous experiences reporting a possible favourable outcome of pregnancy in patients affected by acromegaly and add further information about the behaviour of giant pituitary tumors in patients underwent pregnancy. PMID: 30088454 [PubMed - as supplied by publisher]
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Endocr Metab Immune Disord Drug Targets Source Type: research
Authors: Yamamoto R, Robert Shima K, Igawa H, Kaikoi Y, Sasagawa Y, Hayashi Y, Inoshita N, Fukuoka H, Takahashi Y, Takamura T Abstract A 43-year-old woman with an 8-year history of diabetes, hypertension, and dyslipidemia presented with amenorrhea and convulsion. Her MRI scan revealed a 3.5-cm T2-hyperintense pituitary macroadenoma with suprasellar extension to the frontal lobe and bilateral cavernous sinus invasion. Her serum levels of GH and insulin-like growth factor-I (IGF-I) were elevated to 9.08 ng/mL (normal range:
Source: Endocrine Journal - Category: Endocrinology Tags: Endocr J Source Type: research
Publication date: July–August 2018Source: Reumatología Clínica (English Edition), Volume 14, Issue 4Author(s): Rita Fonseca, Alberto Fernández-Martínez, Roberto Miguélez, Jacqueline Uson
Source: Reumatologia Clinica - Category: Rheumatology Source Type: research
Condition:   Acromegaly Intervention:   Sponsors:   Tulane University;   Chiasma, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Abstract OBJECTIVE: to assess the efficacy and safety after 48 weeks of treatment with pasireotide long-acting-release (PAS-LAR) alone or in combination with pegvisomant in patients with acromegaly. In addition, we assessed the relation between insulin secretion and pasireotide-induced hyperglycemia. DESIGN: The PAPE extension study is a prospective follow-up study until 48 weeks after the core study of 24 weeks. METHODS: 59 out of 61 patients entered the extension study. Efficacy was defined as the percentage of patients achieving IGF-I normalization (≤ 1.2 x the Upper Limit of Normal (ULN)) at 48-we...
Source: European Journal of Endocrinology - Category: Endocrinology Authors: Tags: Eur J Endocrinol Source Type: research
Authors: Iacovazzo D, Hernández-Ramírez LC, Korbonits M Abstract INTRODUCTION: Although most pituitary adenomas occur sporadically, these common tumors can present in a familial setting in approximately 5% of cases. Germline mutations in several genes with autosomal dominant (AIP, MEN1, CDKN1B, PRKAR1A, SDHx) or X-linked dominant (GPR101) inheritance are causative of familial pituitary adenomas. Due to variable disease penetrance and occurrence of de novo mutations, some patients harboring germline mutations have no family history of pituitary adenomas (simplex cases). Areas covered: We summarize the ...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
Authors: Bima C, Chiloiro S, Mormando M, Piacentini S, Bracaccia E, Giampietro A, Tartaglione L, Bianchi A, De Marinis L Abstract INTRODUCTION: Acromegaly, caused in most cases by Growth Hormone (GH)-secreting pituitary adenomas, is characterized by increased skeletal growth and enlargement of the soft tissue, because GH and its effector Insulin-like Growth factor-1 are important regulators of bone homeostasis and have a central role in the longitudinal bone growth and maintenance of bone mass. Areas covered: Despite the anabolic effect of these hormones is well known, as a result of the stimulation of bone turnove...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
Authors: Schilbach K, Schopohl J Abstract INTRODUCTION: Somatostatin analogs are most commonly used in pharmacological treatment of acromegaly. Pegvisomant and dopamine agonists are alternatives, which are used to a lesser extent. Dopamine agonists are the only orally applicable medication but are less effective than the other options. For a large number of patients, life-long pharmacotherapy has to be applied and frequent injections represent a reduction of quality of life for many of them. Areas covered: Recently published evidence for the use of oral octreotide therapy for acromegaly. Expert commentary: Oral oct...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
Authors: Grasso LFS, Auriemma RS, Pivonello R, Colao A Abstract INTRODUCTION: Therapies for acromegaly aim at normalizing hormonal excess and controlling tumor growth . Therapeutic approaches are surgery, pharmacotherapy and radiotherapy. Area covered: This review focuses on the role of medical therapy of acromegaly, comparing the efficacy of somatostatin analogues (SSA), dopamine-agonists (DA) and pegvisomant (PEG), the three available drug classes for treating acromegaly. To clarify the difference in response rates reported in the literature for these therapies, we performed a search for original articles publish...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
More News: Acromegaly | Anatomy | Science | Students | Universities & Medical Training | Zoology